<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Qingjie</style></author><author><style face="normal" font="default" size="100%">Löhr, Christiane V</style></author><author><style face="normal" font="default" size="100%">Dashwood, Roderick H</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Activator protein 2alpha suppresses intestinal tumorigenesis in the Apc(min) mouse.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer letters</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cancer Lett.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adenomatous Polyposis Coli Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">beta Catenin</style></keyword><keyword><style  face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Transformation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Colorectal Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoprecipitation</style></keyword><keyword><style  face="normal" font="default" size="100%">Intestinal Polyps</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factor AP-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Wnt Proteins</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009 Sep 28</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">283</style></volume><pages><style face="normal" font="default" size="100%">36-42</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Activator protein 2alpha (AP-2alpha) is a putative tumor suppressor, and various reports have described the loss or reduction of AP-2alpha expression in cutaneous malignant melanomas, as well as in cancers of the prostate, breast and colon. Previously, AP-2alpha was shown to attenuate beta-catenin/T-cell factor-4 (TCF-4) nuclear interactions and beta-catenin/TCF-4-dependent transcriptional activity in human colorectal cancer cells [Q. Li, R.H. Dashwood, Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and Inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells, J. Biol. Chem. 279 (2004) 45669-45675]. Here, we show that in vivo gene delivery of AP-2alpha suppressed intestinal polyp formation in the Apc(min) mouse, and protected against the development of anemia and splenomegaly. Immunoblot analyses and immunohistochemistry following gene delivery revealed an increase in AP-2alpha expression in the mouse intestinal mucosa and liver. Co-immunoprecipitation experiments provided evidence for interactions between AP-2alpha, beta-catenin, and adenomatous polyposis coli (APC) proteins in mouse intestinal mucosa, as well as in a primary human colorectal cancer. Collectively, these studies support a tumor suppressor role for AP-2alpha in the gastrointestinal tract, and suggest that AP-2alpha represents a novel target for therapeutic intervention in human cancers characterized by dysregulated Wnt signaling.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/19376641?dopt=Abstract</style></custom1></record></records></xml>